- Welcome to Specialised Therapeutics
-
SE Asia (HQ)
+65 3158 9940
-
Australia
1300 798 820
-
New Zealand
+64 9801 0299
Pipeline
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
ABRAXANE® (nanoparticle albumin-bound paclitaxel)
P1
P2
P3
RF
NERLYNX® (neratinib)
P1
P2
P3
RF
ZEPZELCA™ (lurbinectedin)
P1
P2
P3
RF
Mesothelioma (SEALIGHT)
YONDELIS® (trabectedin)
P1
P2
P3
RF
QINLOCK® (ripretinib)
P1
P2
P3
RF
Oncotype DX®
P1
P2
P3
RF
PEMAZYRE® (pemigatinib)
P1
P2
P3
RF
ANNIKO® (penpulimab)
P1
P2
P3
RF
Oregovomab
P1
P2
P3
RF
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
SKYTROFA™ (lonapegsomatropin, developed as TransCon™ hGH)
P1
P2
P3
RF
YORVIPATH™ (palopegteriparatide, developed as TransCon™ PTH)
P1
P2
P3
RF
TransCon™ CNP (navepegritide)
P1
P2
P3
RF
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
APLIDIN® (plitidepsin)
P1
P2
P3
RF
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
APLIDIN® (plitidepsin)
P1
P2
P3
RF
Rigosertib
P1
P2
P3
RF
MINJUVI® (tafasitamab)
P1
P2
P3
RF
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
Anamorelin
P1
P2
P3
RF
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
ILUVIEN® (fluocinolone acetonide intravitreal implant)
P1
P2
P3
RF
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
GLIOLAN® (aminolevulinic acid HCl)
P1
P2
P3
RF
TW001 (edaravone)
P1
P2
P3
RF
To learn more about the clinical trials that are underway and to find out if a study is enrolling patients in your area, please visit www.clinicaltrials.gov